Powder: -20°C for 3 years | In solvent: -80°C for 1 year
LY 178002 is an effective inhibitor of 5-lipoxygenase (5-LPO), phospholipase A2 (IC50: 0.6 μM for 5-lipoxygenase). LY 178002 also inhibits cellular production of LTB4 by human polymorphonuclear leukocytes and displays relatively weak inhibition on cyclooxygenase.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 10,600 | 6-8周 | ||
50 mg | ¥ 13,800 | 6-8周 | ||
100 mg | ¥ 17,500 | 6-8周 |
产品描述 | LY 178002 is an effective inhibitor of 5-lipoxygenase (5-LPO), phospholipase A2 (IC50: 0.6 μM for 5-lipoxygenase). LY 178002 also inhibits cellular production of LTB4 by human polymorphonuclear leukocytes and displays relatively weak inhibition on cyclooxygenase. |
靶点活性 | 5-LPO:0.6 μM, FCO:4.2 μM, COX:, PLA2:6.3 μM |
体外活性 | LY178002 suppresses the generation of LTB4, PLA2 and FCO (IC50s of 0.1, 6.3 and 4.2 μM) . |
体内活性 | LY 178002 (50 mg/kg) inhibits soft tissue swelling in the uninjected paw by 81% and inhibits bone damage in rats. LY178002 (50 mg/kg; p.o.) inhibits the uninjected paw swelling by 75%, in the established FCA model. The minimum effective dose for LY178002 is 10 mg/kg p.o. |
分子量 | 319.46 |
分子式 | C18H25NO2S |
CAS No. | 107889-32-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
LY 178002 107889-32-7 Metabolism Retinoid Receptor LY178002 LY-178002 Inhibitor inhibitor inhibit